XOMA’s SECOND E5 STUDY IS UNDER REVIEW AT FDA
XOMA's SECOND E5 STUDY IS UNDER REVIEW AT FDA, the company reported April 15. FDA sent the firm a letter during the first week of April stating that the agency's analysis of data from a second Xoma multicenter trial for E5 is "ongoing." In the same letter, FDA told Xoma that the company's first large study of the anti-endotoxin for treatment of septic shock "does not provide sufficient evidence of efficacy to support product licensure." FDA's determination that the original trial alone will not support licensure is not a surprise: the agency's Vaccines and Related Biological Products Advisory Committee reviewed that study at its Sept. 4 meeting ("The Pink Sheet" Sept. 9, p. 17). The advisory committee requested further analysis of E5's efficacy. FDA's findings on the first trial do not "in any way imply a delay or setback in the agency's review of E5," Xoma maintained. Xoma presented data from the second study to the advisory committee, and the initial response of the committee was that the results apparently did not substantiate the efficacy results of the first trial. Xoma VP-Clinical Research Samuel Saks, MD, told the panel, however, that an analysis of the two studies together showed an increase in survival among septic shock patients. Xoma has presented the agency with data from the second trial as well as a "meta-analysis" of the two studies, the company said. "When the two trials are combined," the company added, "we believe the safety and effectiveness of E5 are clearly demonstrated." FDA's review of the meta-analysis also is under way, Xoma explained.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth